ReviewCurrent rheumatology reports2007
Monitoring cartilage turnover.
Review in Current rheumatology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 62 citations in OpenAlex.
- Effect of Resveratrol on Serum Levels of Type II Collagen and Aggrecan in Patients with Knee Osteoarthritis: A Pilot Clinical Study.BioMed research international · 2021Trial
- Concerted actions by MMPs, ADAMTS and serine proteases during remodeling of the cartilage callus into bone during osseointegration of hip implants.Bone reports · 2020Article
- Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-α Inhibitors.Journal of clinical medicine · 2020Article
- Combating Osteoarthritis through Stem Cell Therapies by Rejuvenating Cartilage: A Review.Stem cells international · 2018Review
- Diagnostic value of combined serum marker changes and quantitative MRI evaluation of cartilage volume of tibial plateau in a surgically-induced osteoarthritis dog model.The Journal of international medical research · 2017Article
- Article
- Republished: Value of biomarkers in osteoarthritis: current status and perspectives.Postgraduate medical journal · 2014Article
- Value of biomarkers in osteoarthritis: current status and perspectives.Annals of the rheumatic diseases · 2013Review
- Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis.Osteoarthritis and cartilage · 2011Article
- The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis.Nature reviews. Rheumatology · 2010Review
- 2-Deoxy-D-glucose regulates dedifferentiation through beta-catenin pathway in rabbit articular chondrocytes.Experimental & molecular medicine · 2010Article
- First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis.PloS one · 2010Article
- Genome-wide linkage analysis of quantitative biomarker traits of osteoarthritis in a large, multigenerational extended family.Arthritis and rheumatism · 2010Article
- Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?Rheumatology international · 2010Review
- New methods to diagnose and treat cartilage degeneration.Nature reviews. Rheumatology · 2009Review
- Cartilage homeostasis in health and rheumatic diseases.Arthritis research & therapy · 2009Review
- Biomarkers associated with clinical phenotypes of hand osteoarthritis in a large multigenerational family: the CARRIAGE family study.Osteoarthritis and cartilage · 2008Article
- The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?Arthritis research & therapy · 2008Review
- Cells of the synovium in rheumatoid arthritis. Chondrocytes.Arthritis research & therapy · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In arthritic diseases, the stability of the extracellular matrix of articular cartilage is compromised by extensive proteolytic breakdown associated with alterations of synthesis of the proteins of the tissue leading to cartilage loss. This article reviews developments in assays of biochemical markers of cartilage matrix turnover and studies investigating their use. Because type II collagen and aggrecan are the most abundant proteins of the cartilage matrix, current biochemical markers are based mainly on immunologic reagents detecting their synthesis and degradation. Clinical studies indicate that some markers of type II collagen may be useful to predict disease progression in osteoarthritis and rheumatoid arthritis. Conversely, major achievements have been made in the development of immunoassays detecting the various fragments of aggrecan released by matrix metalloproteases or aggrecanases, but their use has been limited mostly to investigating cartilage turnover in ex vivo experiments. Because of the complexity of the mechanisms involved in arthritic joint damage, only a combination of different biochemical markers reflecting the various aspects of synthesis and degradation of matrix molecules will likely provide efficient cartilage turnover monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.